Guardant360, the gold standard in comprehensive liquid biopsy, helps oncologists maximize targeted treatment options for their advanced cancer patients. Ever since we pioneered the field of comprehensive liquid biopsy in 2014, we have continued to innovate with a singular focus on transforming cancer care.
Blood-based cancer DNA testing is our main focus. It’s what we do best. It’s why the technology has continued to improve so rapidly since we introduced Guardant360. Today we are pleased to announce significant performance improvements to Guardant360. We have improved its industry-leading performance while adding more druggable targets to the panel. Additionally, we’re introducing a simplified Guardant360 report, more online physician decision-support tools, and patient-access resources.
Guardant360 identifies somatic genomic alterations in circulating tumor DNA that are sensitizing or resistant to targeted therapies. The test has been used by more than 3,000 oncologists to help nearly 30,000 advanced cancer patients. Everything we’ve learned about tumor biology and bioinformatics from working at this scale has helped us further optimize Guardant360 for increased clinical sensitivity and utility.
Put simply: our technology gets better with every test we run. And even to our own surprise, the pace of technology improvement has been getting steeper as the amount of data we collect grows. But this actually makes perfect sense — issues that occur only every one or two thousand samples can only be solved by processing tens of thousands of blood samples a year.
A New, More Sensitive 73-Gene Panel
Among comprehensive liquid biopsies, the new 73-gene Guardant360 panel covers the most sensitizing and resistance markers for targeted therapies. How does this affect patients? The increased coverage will give physicians more opportunities to direct patient care with BRAF/MEK inhibitors, NTRK3 inhibitors, PARP inhibitors, tyrosine kinase inhibitors, MET inhibitors, and more. Additionally, bioinformatics and biochemistry innovations now allow us to confidently call alterations down to allele frequencies of 0.02% in some cases. That’s important because more than half of the alterations Guardant360 has ever reported were detected at an allele frequency of less than 0.4%.
We know physicians are busy and we are always looking for ways to save them time. We are excited to introduce an updated Guardant360 report designed to reduce the effort spent interpreting results. The new report helps clinicians more quickly identify important drug targets and known resistance alterations detected by Guardant360. We’ve also added new features designed to make it easier to identify and enroll patients into nearby clinical trials.
iPhone App for Reports on the Go
This enhanced Guardant360 experience also includes an improved, HIPAA-compliant, iPhone application that physicians can use to easily access and explore their patients’ reports on-the-go. They can also securely share Guardant360 reports with colleagues, view historical trends in druggable alterations from prior reports, and access support services from our team of medical science liaisons.
myGuardant Patient Portal
The new Guardant360 also provides an enhanced experience for patients. Through the myGuardant patient portal, patients can track sample progress and view their reports upon release by their physician, access financial assistance programs, and find educational resources.
We know our work is not complete, and we will continue to improve our products. Every test we run helps make Guardant360 better. We thank every patient and oncologist who have made us part of their practice and care. These improvements, and future improvements to Guardant360, are only possible by all the stakeholders working together.
Want to learn more?
If you would like to learn more about the enhanced Guardant360, or schedule a consultation with a member of our Medical Affairs team, please contact your local Account Executive